IPP Bureau
Exscientia and Sanofi collaborate for AI-driven precision-engineered medicine
By IPP Bureau - January 08, 2022
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Maharasthra Health Minister inaugurates BSV research centre at Airoli, Maharashtra
By IPP Bureau - January 07, 2022
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Pfizer and BioNTech to develop first mRNA-based Shingles vaccine
By IPP Bureau - January 07, 2022
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Lilly and Entos collaborate for therapies in multiple neurologic indications
By IPP Bureau - January 07, 2022
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron
By IPP Bureau - January 07, 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
Lupin launches Molnulup to treat Covid-19
By IPP Bureau - January 07, 2022
The drug is priced at Rs 2000 for a course of 40 tablets
Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
By IPP Bureau - January 07, 2022
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
AstraZeneca and Neurimmune to develop and commercialise NI006
By IPP Bureau - January 07, 2022
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Merck KGaA to acquire biopharma CDMO Exelead for $780 million
By IPP Bureau - January 07, 2022
The transaction is expected to close in the first quarter of 2022
Barentz appoints Daniel Hitz as CEO, APAC
By IPP Bureau - January 07, 2022
Hitz shall assume new role from January 17th, 2022
Aurobindo Pharma rolls out Molnaflu in India
By IPP Bureau - January 06, 2022
The brand is now available pan-India through their distribution partner
Yashoda Hospitals performs region’s first double-lung transplant
By IPP Bureau - January 06, 2022
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
Margins under pressure; domestic market growth to slow down: Nirmal Bang
By IPP Bureau - January 06, 2022
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Biotium introduces unique super-sensitive RNA Prestain Loading Dye
By IPP Bureau - January 06, 2022
EMBER500RNA Prestain Loading Dye allows single-step denaturing, loading, and bright RNA staining on regular agarose gels
Thermo Fisher Scientific acquires PeproTech for US $1.85 bn
By IPP Bureau - January 06, 2022
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
